Aberdeen Group plc lowered its stake in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 45.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 474,953 shares of the company’s stock after selling 401,505 shares during the quarter. Aberdeen Group plc’s holdings in WAVE Life Sciences were worth $1,757,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of WVE. Readystate Asset Management LP acquired a new stake in shares of WAVE Life Sciences in the second quarter worth approximately $27,465,000. Squarepoint Ops LLC increased its position in WAVE Life Sciences by 68.0% during the second quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock worth $14,766,000 after purchasing an additional 1,029,052 shares during the last quarter. Renaissance Technologies LLC increased its position in WAVE Life Sciences by 152.6% during the first quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after purchasing an additional 360,800 shares during the last quarter. Bank of New York Mellon Corp increased its position in WAVE Life Sciences by 12.4% during the first quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company’s stock worth $2,619,000 after purchasing an additional 39,759 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in WAVE Life Sciences by 34.7% during the third quarter. Alps Advisors Inc. now owns 261,053 shares of the company’s stock worth $966,000 after purchasing an additional 67,287 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
WVE has been the topic of a number of research analyst reports. Ladenburg Thalmann & Co. Inc. began coverage on shares of WAVE Life Sciences in a report on Thursday, October 1st. They issued a “buy” rating and a $10.00 price target on the stock. Zacks Research cut shares of WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Mizuho dropped their price objective on WAVE Life Sciences from $27.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, August 4th. JPMorgan Chase & Co. assumed coverage on WAVE Life Sciences in a research report on Wednesday, September 23rd. They issued a “neutral” rating on the stock. Finally, UBS Group started coverage on WAVE Life Sciences in a report on Thursday, October 15th. They issued a “buy” rating and a $11.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, WAVE Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.44.
Check Out Our Latest Report on WAVE Life Sciences
WAVE Life Sciences Price Performance
NASDAQ:WVE opened at $2.56 on Friday. The firm has a 50-day moving average of $3.53 and a two-hundred day moving average of $6.71. WAVE Life Sciences Ltd. has a 1-year low of $2.55 and a 1-year high of $21.73.
WAVE Life Sciences (NASDAQ:WVE – Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $13.16 million during the quarter, compared to the consensus estimate of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%. On average, research analysts expect that WAVE Life Sciences Ltd. will post -1.08 EPS for the current year.
WAVE Life Sciences Company Profile
WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.
Further Reading
- Five stocks we like better than WAVE Life Sciences
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for WAVE Life Sciences Ltd. (NASDAQ:WVE – Free Report).
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
